BRAF and melanoma: The standard of care in front-line advanced melanoma in the US is one of 2 doublets (nivolumab/ipilimumab or nivolumab/relatlimab) based on improved PFS over PD-1 monotherapy on the results of pivotal trials.38-41 Further, in PD-1 naïve BRAF mutant melanoma, initial treatment with nivolumab/ipilimumab followed by targeted therapy in the event of progression is associated with superior OS, compared to the reverse sequence.42 Based on this, combination immunotherapy as the initial therapy of choice for most advanced melanoma patients in the US.